1. Home
  2. GRDN vs ANIP Comparison

GRDN vs ANIP Comparison

Compare GRDN & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guardian Pharmacy Services Inc.

GRDN

Guardian Pharmacy Services Inc.

HOLD

Current Price

$30.71

Market Cap

1.7B

ML Signal

HOLD

ANIP

ANI Pharmaceuticals Inc.

HOLD

Current Price

$82.01

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRDN
ANIP
Founded
2004
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Retail-Drug Stores and Proprietary Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
2.0B
IPO Year
2024
N/A

Fundamental Metrics

Financial Performance
Metric
GRDN
ANIP
Price
$30.71
$82.01
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$33.33
$107.33
AVG Volume (30 Days)
276.6K
574.8K
Earning Date
11-10-2025
02-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.28
1.67
Revenue
$1,389,638,000.00
$826,880,000.00
Revenue This Year
$19.50
$44.35
Revenue Next Year
$0.48
$11.13
P/E Ratio
$108.55
$47.47
Revenue Growth
18.68
48.87
52 Week Low
$17.78
$54.10
52 Week High
$37.43
$99.50

Technical Indicators

Market Signals
Indicator
GRDN
ANIP
Relative Strength Index (RSI) 52.89 49.29
Support Level $29.07 $78.10
Resistance Level $31.11 $86.97
Average True Range (ATR) 1.51 3.52
MACD 0.03 -0.20
Stochastic Oscillator 76.44 57.73

Price Performance

Historical Comparison
GRDN
ANIP

About GRDN Guardian Pharmacy Services Inc.

Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Share on Social Networks: